by Genova Marketing Department

On October 9, under the leadership of Mao Hua, the partner and managing director of Frost Sullivan, a world-famous consulting company, the pharmaceutical field team visited Genova Biotech（Changzhou） and had an in-depth discussion with Dr. Shen Chun, chairman of the company, and the business team on the current market situation and future development of recombinant protein drugs.

At the meeting, Dr. Shen Chun first introduced the current market situation in the field of recombinant protein: recombinant protein drugs are the bright pearl of biological drugs. In 1982, the world's first recombinant protein drug - recombinant human insulin was listed, which opened the glorious history of the development of recombinant protein drugs. The 1990s was a golden period for the development of recombinant protein drugs. A number of heavy recombinant protein drugs were approved to market during this period, which provided a new means for disease treatment and created considerable economic benefits while benefiting mankind. Recombinant protein drugs have definite curative effect, are indispensable in disease treatment, are difficult to develop, have high barriers, and are less affected by the current price reduction policy of medical reform. It is the most noteworthy pharmaceutical investment field at this stage. Meanwhile, insulin and other recombinant protein drugs correspond to large diseases with high incidence rate and large number of diseases in diabetes and other diseases. The market space is far from reaching the ceiling.

The general manager of Maohua said that the enterprise should grasp the development opportunity of domestic recombinant protein drugs. At present, the domestic biopharmaceutical field is booming. A number of excellent domestic recombinant protein drug companies have been born. Various recombinant protein drugs are undergoing domestic replacement, product upgrading and industry development market expansion. To grasp the good opportunity for the development of domestic recombinant protein drugs, Genova, as an excellent domestic recombinant protein company, is very worthy of expectation.